Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation

The NovoTTF-100A is a device that emits alternating electric fields and it is approved for the treatment of recurrent glioblastoma. It works by perturbing tumor cells during mitosis as they enter anaphase leading to aneuploidy, asymmetric chromosome segregation and cell death with evidence of increa...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Eric T, Lok, Edwin, Swanson, Kenneth D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4380964/
https://www.ncbi.nlm.nih.gov/pubmed/25620708
http://dx.doi.org/10.1002/cam4.421

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4380964/
https://www.ncbi.nlm.nih.gov/pubmed/25620708
http://dx.doi.org/10.1002/cam4.421

Ejemplares similares